The total human evidence base, as of this writing, consists of the following: 1) a Phase I safety trial of 42 healthy volunteers that was registered in 2015, canceled in 2016, and never published, 2) a retrospective case series of 12 patients with knee pain, no control group, and no validated outcome measure, and 3) a 2025 pilot safety study involving two healthy adults who received intravenous infusions at a single private clinic in Florida
Non-Classical Pathways Unlike full-length hGH, which exerts its lipolytic effects through the classical GH receptor and JAK-STAT signaling, AOD-9604 operates through alternative, receptor-independent pathways
30 capsules included
ACS Pharmacol Trans Sci 2(5):353360 Igreja B, Pires NM, Wright LC, Soares-da-Silva P (2019b) Effects of zamicastat treatment in a genetic model of salt-sensitive hypertension and heart failure